RT Journal Article
SR Electronic
T1 Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.13.20212233
DO 10.1101/2020.10.13.20212233
A1 Paul Z. Chen
A1 Niklas Bobrovitz
A1 Zahra Premji
A1 Marion Koopmans
A1 David N. Fisman
A1 Frank X. Gu
YR 2020
UL http://medrxiv.org/content/early/2020/11/10/2020.10.13.20212233.abstract
AB Understanding the factors that mediate overdispersion in SARS-CoV-2 transmissibility is crucial towards mitigating the COVID-19 pandemic. Using a systematically developed dataset, we meta-analyze respiratory viral loads (rVLs) of SARS-CoV-2, SARS-CoV-1 and influenza A(H1N1)pdm09 from 15 countries and model infectiousness by shedding viable virus via droplets and aerosols. Our results indicate heterogeneity in rVL as an intrinsic virological factor facilitating greater overdispersion in the COVID-19 pandemic than in the 2009 H1N1 pandemic. For COVID-19, case heterogeneity remains broad throughout the infectious period, including for pediatric and asymptomatic infections. Many cases inherently present minimal transmission risk, whereas highly infectious individuals shed tens to thousands of SARS-CoV-2 virions/min via droplets and aerosols while breathing, talking and singing. Coughing increases the contagiousness, especially in close contact, of symptomatic cases relative to asymptomatic ones. Our findings show how individual case variations influence SARS-CoV-2 transmissibility and present considerations for disease control.One Sentence Summary Intrinsic case variation in respiratory viral load facilitates broad overdispersion in SARS-CoV-2 transmissibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Toronto COVID-19 Action Fund. P.Z.C. was supported by the NSERC Vanier Scholarship (608544). D.N.F. was supported by the Canadian Institutes of Health Research (Canadian COVID-19 Rapid Research Fund, OV4-170360). F.X.G. was supported by the NSERC Senior Industrial Research Chair.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request. All raw data, code and model outputs from this study will be made publicly available in online repositories after peer review. Search strategies for the systematic review are shown in Supplementary Tables 1-5. The systematic review protocol was prospectively registered on PROSPERO (registration number, CRD42020204637).